Tesamorelin vs CJC-1295 (Mod GRF 1-29)
Independent, side-by-side comparison of Tesamorelin and CJC-1295 (Mod GRF 1-29): mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.
Live price snapshot
Tesamorelin
CJC-1295 (Mod GRF 1-29)
Tesamorelin
Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically the full 44-amino-acid GHRH sequence with a single N-terminal trans-3-hexenoyl fatty-acid modification. That…
Live lowest price: $44.99 across 12 vendors
Full Tesamorelin profileCJC-1295 (Mod GRF 1-29)
CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF 1-29) is a 30-amino-acid analog of the first 29 residues of endogenous Growth Hormone Releasing Hormone (GHRH), with four strategic substitutions (D-Ala┬▓…
Live lowest price: $29.00 across 5 vendors
Full CJC-1295 (Mod GRF 1-29) profileSide-by-side comparison
| Attribute | Tesamorelin | CJC-1295 (Mod GRF 1-29) |
|---|---|---|
| Category | Growth Hormone / IGF-1 Axis | Growth Hormone / IGF-1 Axis |
| Research Stage | FDA Approved | Phase 2 (clinical development discontinued) |
| Mechanism of Action | Tesamorelin activates the same GHRH receptor (GHRHR) as endogenous GHRH and CJC-1295 / MOD-GRF 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl N-terminal modification. 1. GHRH receptor agonism (Gs / cAMP / PKA / CREB pathway) -… | MOD-GRF 1-29 exerts its effect through a single, well-characterized receptor: the GHRH receptor (GHRHR) on anterior-pituitary somatotroph cells. The signaling cascade is the same as endogenous GHRH; the difference is pharmacokinetics. 1. GHRH receptor agonism… |
| Half-Life | 30-50 minutes (plasma) | ~30 minutes (without DAC / MOD-GRF 1-29); 8+ days (with DAC, due to covalent albumin binding) |
| Typical Dose Range | 1,000–2,000 mcg (1–2 mg) daily | Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly |
| Dosing Frequency | Once daily subcutaneous injection | 1–3 times daily, typically before bed and/or upon waking |
| Administration | subcutaneous | Subcutaneous |
| Side Effects | Tesamorelin has a well-characterized side-effect profile from the FDA approval program, which is a significant advantage over non-approved GHRH analogs. Common (10% in Phase 3 trials) - Injection site reactions — erythema, pruritus, pain at site; most frequent… | Expected / benign - Injection-site reaction — mild redness, itching, small bump; 24-48 hour resolution - Facial flushing / warmth 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2 - Mild nausea in first week at… |
| Molecular Weight | 5135.9 Da | 3367.9 Da |
| Common Vial Sizes | 2mg, 10mg | 2mg, 5mg |
Price History
4 data points- OF
- Unknown
- Nova Peptides
- VANDL Labs
- Ion Peptide
Price History
2 data points- VANDL Labs
- Ion Peptide
Tesamorelin — potential benefits
- Reduction of visceral adipose tissue (~18% at 26 weeks, FDA-label indication)
- Reduction of hepatic fat content (NAFLD off-label indication)
- Elevated IGF-1 within age-adjusted reference range
- Preserved pulsatile GH release (vs continuous with CJC-1295-DAC)
- Improved body composition (VATΓåô, lean mass preserved)
- Potential cognitive improvement in GH-axis-deficient populations
- Sustained effect at 52 weeks with continued dosing
- FDA-approved ΓÇö the only GHRH secretagogue with that status
CJC-1295 (Mod GRF 1-29) — potential benefits
- Preserves physiologic pulsatile GH secretion
- Stimulates endogenous GH release (2-5x baseline per pulse)
- 3-5x greater GH response when stacked with ipamorelin
- Modest IGF-1 elevation (1.5-2x baseline)
- Improved sleep depth and architecture
- Enhanced recovery from exercise and injury
- Body composition improvements (lean mass preservation, modest fat loss)
- Lower desensitization risk vs CJC-1295 with DAC
Frequently asked
What's the difference between Tesamorelin and CJC-1295 (Mod GRF 1-29)?
Tesamorelin is a growth hormone / igf-1 axis that tesamorelin activates the same ghrh receptor (ghrhr) as endogenous ghrh and cjc-1295 / mod-grf 1-29, but with a distinct pharmacokinetic profile driven by its trans-3-hexenoyl…. CJC-1295 (Mod GRF 1-29) is a growth hormone / igf-1 axis that mod-grf 1-29 exerts its effect through a single, well-characterized receptor: the ghrh receptor (ghrhr) on anterior-pituitary somatotroph cells. the signaling cascade is the same…. The two differ in mechanism, half-life (30-50 minutes (plasma) vs ~30 minutes (without DAC / MOD-GRF 1-29); 8+ days (with DAC, due to covalent albumin binding)), and typical dose range.
Which has the longer half-life, Tesamorelin or CJC-1295 (Mod GRF 1-29)?
Tesamorelin has a half-life of 30-50 minutes (plasma). CJC-1295 (Mod GRF 1-29) has a half-life of ~30 minutes (without DAC / MOD-GRF 1-29); 8+ days (with DAC, due to covalent albumin binding). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Tesamorelin or CJC-1295 (Mod GRF 1-29)?
Current lowest live price on BodyHackGuide: Tesamorelin from $44.99, CJC-1295 (Mod GRF 1-29) from $29.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.
Can you stack Tesamorelin and CJC-1295 (Mod GRF 1-29)?
Stacking depends on mechanism overlap, safety profile, and goals. Tesamorelin and CJC-1295 (Mod GRF 1-29) should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Live listings from the vendors we track, refreshed continuously.
Related comparisons
Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.